CAR-T therapy toxicities: the importance of macrophages in their development and possible targets for their management
Abstract CAR-T cell therapies have risen to prominence over the last decade, and their indications are increasing with several products approved as early as second line in Large B Cell non-Hodgkin Lymphomas. Their major toxicities are the cytokine release syndrome (CRS) and the Immune-effector Cell...
Saved in:
Main Authors: | Joseph Norton, Patrick Stiff |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2025-01-01
|
Series: | Discover Oncology |
Online Access: | https://doi.org/10.1007/s12672-025-01776-0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies
by: Fang Wang, et al.
Published: (2025-02-01) -
Tumor Cells and Tumor-Associated Macrophages: Secreted Proteins as Potential Targets for Therapy
by: Marc Baay, et al.
Published: (2011-01-01) -
Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
by: Nan Li, et al.
Published: (2023-01-01) -
Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
by: Shangjun Sun, et al.
Published: (2018-01-01) -
Macrophage-Based Therapies for Atherosclerosis Management
by: Renyi Peng, et al.
Published: (2020-01-01)